EUVIMEDOpdag EUVIMED
Crossref

Mechanistic insights into the inhibition of drug‐resistant cytomegalovirus by letermovir and ganciclovir

Noriaki Sato iD, Atsuko Shiraki, Tohru Daikoku, Masaya Takemoto, Yoshinori Takemura, Kaoru Sakai, Seiya Imoto, Motoko Yanagita, Kazunari Tanabe, Kimiyasu Shiraki

British Journal of Pharmacology · 2026

DOI: 10.1111/bph.70239 ↗

At a glance

Journal article in British Journal of Pharmacology, 2026. Written by Noriaki Sato and 9 co-authors. Institution: Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Major MEDLINE topics: Cytomegalovirus, Ganciclovir, Antiviral Agents, Drug Resistance, Viral. Cited 1 times so far (Crossref); 43 references. Funded by: Merck Sharp and Dohme K.K., Takeda Science Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Letermovir and ganciclovir are used to prevent cytomegalovirus (CMV) infection, but the generation of resistant viruses and the interactions between wild and resistant CMV have not been studied. We evaluated the effect of letermovir/ganciclovir on the release of the wild‐type and letermovir/ganciclovir‐resistant CMV in their coinfected or superinfected cells. Experimental Approach We analysed the extracellular CMV infectivity released from CMV‐infected cells treated with letermovir and ganciclovir. Subsequently, we characterized growth of letermovir/ganciclovir‐resistant viruses in wild‐type CMV‐infected cells in the presence of letermovir/ganciclovir, respectively. Key Results The number of infectious cells resuming viral replication after letermovir/ganciclovir removal decreased over time, and the CMV‐infected cells treated with letermovir or ganciclovir remained infectious for 1 month. During the treatment course, letermovir‐/ganciclovir‐resistant viruses arise from CMV infection foci, and we investigated the proliferation of resistant viruses in the presence of letermovir/ganciclovir. Letermovir inhibited superinfected CMV release by inhibiting the superinfected CMV from using the DNA terminase‐packaging complex pathway occupied by a prior infected CMV. Co‐infection and superinfection of ganciclovir‐resistant CMV in wild‐type CMV‐infected cells inhibited viral release by inhibiting DNA synthesis by ganciclovir phosphorylated by wild‐type UL97 . These results suggested that letermovir‐resistant CMV emerging in wild‐type CMV‐infected cells would not easily spread to the surrounding wild‐type CMV‐infected cells in CMV‐infected patients under letermovir. Conclusion and Implications Despite different mechanisms of action, both drugs inhibited the spread of newly emerging resistant viruses around wild‐type CMV‐infected lesions during letermovir/ganciclovir treatment, suggesting the practical use of both drugs and strategies for treating drug‐resistant CMV.

Subjects

MeSH terms (MEDLINE)

CytomegalovirusGanciclovirAntiviral AgentsDrug Resistance, ViralAcetatesQuinazolinesHumansVirus ReplicationCytomegalovirus Infections

Author keywords

Co‐infectioncytomegalovirusganciclovirletermovirresistancesuperinfection

Substances

letermovirGanciclovirAntiviral AgentsAcetatesQuinazolines

Authors and institutions

  • Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Anesthesiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Microbiology, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan.
  • Department of Anesthesiology, Toyama Nishi General Hospital, Toyama, Japan.
  • Kidney Transplant Center, Shonan Kamakura General Hospital, Kanagawa, Japan.

ORCID profiles: Noriaki Sato

Funding

  • Merck Sharp and Dohme K.K.
  • Takeda Science Foundation

Cite

APA

Sato, N., Shiraki, A., Daikoku, T., Takemoto, M., Takemura, Y., Sakai, K., Imoto, S., Yanagita, M., Tanabe, K., & Shiraki, K. (2026). Mechanistic insights into the inhibition of drug‐resistant cytomegalovirus by letermovir and ganciclovir. British Journal of Pharmacology. https://doi.org/10.1111/bph.70239

Vancouver

Sato N, Shiraki A, Daikoku T, Takemoto M, Takemura Y, Sakai K, et al. Mechanistic insights into the inhibition of drug‐resistant cytomegalovirus by letermovir and ganciclovir. British Journal of Pharmacology. 2026. doi:10.1111/bph.70239

BibTeX
@article{Sato2026,
  author = {Sato, Noriaki and Shiraki, Atsuko and Daikoku, Tohru and Takemoto, Masaya and Takemura, Yoshinori and Sakai, Kaoru and Imoto, Seiya and Yanagita, Motoko and Tanabe, Kazunari and Shiraki, Kimiyasu},
  title = {Mechanistic insights into the inhibition of drug‐resistant cytomegalovirus by letermovir and ganciclovir},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70239}
}
Start for free →